256
Participants
Start Date
November 7, 2024
Primary Completion Date
April 30, 2029
Study Completion Date
June 30, 2029
Tirzepatide
Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
Pioglitazone
Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
Sitagliptin
Sitagliptin: will be administered as a 100mg dose once daily.
Metformin HCI XR
Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
RECRUITING
University Health System Texas Diabetic Institute, San Antonio
RECRUITING
UT Health Science Center, San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
The University of Texas Health Science Center at San Antonio
OTHER